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GM1-gangliosidosis is a lysosomal storage disorder caused by a deficiency of β-galactosidase. 
It is mainly characterized by progressive neurodegeneration and in its most severe infantile 
form it leads to death before the age of four. We have performed molecular analysis of five 
patients with the infantile form of GM1-gangliosidosis originating from the Middle East 
(two from Saudi Arabia and three from the United Arab Emirates). We have identified four 
novel mutations and one previously reported mutation in the GLB1 gene. The first novel 
mutation found in the homoallelic state in a patient from Saudi Arabia, is a c.171C>G 
transversion in exon 2 which creates a premature stop codon. Northern blot analysis in 
fibroblasts from the patient showed no mRNA and expression studies in COS-1 cells showed 
complete absence of the 85kDa precursor protein and no catalytic activity. The second novel 
mutation is a splicing error in intron 2, c.245+1G>A. This mutation was found in the 
heteroallelic state in a patient from Saudi Arabia, the second mutation being the previously 
described c.145C>T mutation. The third novel mutation is a missense mutation in exon 4, 
c.451G>T, found in the homoallelic state in a patient from the United Arab Emirates. 
Expression studies of this mutation in COS-1 cells showed complete absence of the 85kDa 
precursor protein and no catalytic activity. The fourth novel mutation is a splicing mutation 
in intron 8, c.914+4A>G, found in the homoallelic state in two siblings from the United Arab 
Emirates. This study has revealed genetic heterogeneity of the β-galactosidase deficiency in 
the Arabic population. © 2004 Wiley-Liss, Inc. 
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INTRODUCTION 
GM1-gangliosidosis (MIM# 230500) is an inborn error of metabolism caused by deficiency of a specific 
lysosomal hydrolase, β-galactosidase (E.C 3.2.1.23) which catalyses the hydrolysis of terminal β-galactose 
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linkages in ganglioside GM1 and other carbohydrate-containing compounds. The disorder is mainly characterized 
by progressive neurodegeneration and has been classified into three clinical forms: infantile (type I), late infantile 
or juvenile (type 2) and adult or chronic (type 3) (Suzuki et al., 2001). The clinical manifestation of the most 
severe infantile form includes rapidly progressive CNS involvement, facial and skeletal abnormalities and 
visceromegaly. Patients rarely survive for more than a few years. Deficiency in β-galactosidase can also result in 
Morquio disease type B (MIM# 253010), a characteristic mucopolysaccharidosis free of neurological symptoms 
(Callahan et al., 1999; Suzuki et al., 2001). Furthermore, patients with infantile GM1-gangliosidosis who also have 
cardiac involvement have been shown to be deficient in both the β-galactosidase and the β-galactosidase related 
protein, also known as elastin binding protein, which results from the GLB1 gene by alternative splicing (Privitera 
et al., 1998; Morrone et al., 2000). 
The β-galactosidase gene (GLB1) has been mapped on chromosome 3 (3p21.33) and has been cloned and 
characterized (Oshima et al., 1988; Morreau et al., 1989). The gene contains 16 exons and encodes a precursor 
protein approximately 70kDa which is co-translationally modified into a glycosylated form of 85kDa and 
processed in lysosomes into a 64kDa  mature enzyme (D’Azzo et al., 1982; Nanba et al., 1988). A total of 48 
mutations have been reported (http://uwcmm/1s.uwcm.ac.uk/uwcm/mg/search/119987.html). Of these, 38 are 
missense/non-sense mutations, three are splicing mutations, five are small insertions and two are duplications.  
In this study we report four new mutations in five patients with the infantile form of GM1-gangliosidosis 
originating from the Middle East.  
 
MATERIALS AND METHODS 
Patients  
Five patients with the infantile form of GM1-gangliosidosis from the Middle East were included in the present 
study, two from Saudi Arabia and three from the United Arab Emirates. Their diagnosis was based on the clinical 
history and confirmed by the measurements of β-galactosidase activity in leucocytes or fibroblasts. 
Mutation Analysis  
Genomic DNA was extracted from peripheral blood or skin fibroblasts of affected patients according to 
standard methods. All the 16 exons of the β-galactosidase gene and their flanking intronic regions were amplified 
by PCR and automated sequencing was carried out using the Perkin Elmer “Big Dye Terminator Cycle Sequencing 
Ready Reaction Kit” as described by the manufacturer. Electrophoresis and sequence analysis followed on an ABI 
PRISM 310 Genetic Analyser.  
The oligonucleotides used for PCR reactions are as published by Silva et al. (1999) except for exons 
1,2,6,14,15,16 which are the following:  
 
Exon 1 sense : 5’-CCTGGGCGCCGACTGCAGAG-3’   
Exon 1 antisense : 5’-CCTAGCAATGCCTCCCCGTA-3’  
Exon 2 sense : 5’-AAGGTGGAAGTTCTCATGTG-3’ 
Exon 2 antisense : 5’-TGTTCAGGCCTAGGTGAGAG-3’ 
Exon 6 sense : 5’-AGGATCTCCTCATTTTTCCCT-3’ 
Exon 6 antisense : 5’-TAAGCTGCAATTTCTGTTAC-3’ 
Exon 14 sense : 5’-ACCCTCAATTCAATTGTCAT-3’ 
Exon 14 antisense : 5’-AACCTTAGTCTTGACAGTGT-3’ 
Exon 15 sense : 5’-GAATTCAAACCCTTCCCATG-3’ 
Exon 15 antisense : 5’-CAGCTCACTGTGCTCTGTTT-3’ 
Exon 16 sense : 5’-TGGGGTTGATGGTTCTCTGT-3’ 
Exon 16 antisense : 5’-CATGACAGGGAGGATCTG-3’ 
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Northern Blot Analysis  
Total RNA and polyA+RNA were isolated from cultured fibroblasts using the Oligotex and RNAeasy RNA 
purification Kits (Qiagen) and Northern Blot analysis was performed. As a probe a 0.8 kb length human β-
galactosidase cDNA was used. To compare the quantity and quality of different RNA samples, the Northern blot 
was also hybridised with a β-actin probe. The intensities of β-gal mRNA bands were normalized by calculating 
their ratios to the intensities of β-actin mRNA bands.  
Expression Studies 
In vitro mutagenesis of human β-galactosidase cDNA was carried out using the method of Higuchi et al (1988) 
to construct the mutated vectors. As a PCR template the mammalian expression vector pcDX was used.  
For the c.171C>G mutation the primers used were:  
 
3040 sense: 5’-TGCAGGTCGACTCTAGAGGATC-3’ 
T57X anti: 5’-GGCACACGGGACTAGTGAATGCTTC-3’ 
T57X sense: 5’-GAAGCATTCACTAGTCCCGTGTG-3’ 
H anti:  5’-TCGTGGACTCCATTGAGGGGTGAAGAG-3’ 
 
For the c.451G>T mutation the primers used were: 
 
3040 sense: 5’-TGCAGGTCGACTCTAGAGGATC-3’ 
D151Y anti: 5’-GGTAATCTGGGTAGGAGGAGCGGAG-3’ 
D151Y sense: 5’-CTCCGCTCCTCCTACCCAGATTACC-3’ 
H anti:  5’-TCGTGGACTCCATTGAGGGGTGAAGAG-3’ 
 
The mutations of interest were excised from PCR products using two restriction endonucleases each of which 
has only one recognition site in the GLB1 cDNA. The restriction enzymes used were the XbaI (5’restriction site) 
and the DraIII (3’ restriction site). The pcDX vector which contained the wild type GLB1 cDNA was restricted at 
two unique endonuclease sites to excise the corresponding wild type fragment. The fragment carrying the mutation 
was then ligated into the plasmids, using the DNA Ligation kit ver.2 by Takara Biomedicals. 
Normal and mutant vectors were transiently overexpressed into African green monkey kidney cells (COS-1) 
according to Sambrooks et al. (1989). Transfected COS-1 cells were cultured and 48 hours post transfection the 
activity of the β-galactosidase enzyme was assayed with the artificial 4-methylumbelliferyl beta-D-
galactopyranoside substrate, as described by Caciotti et al. (2003). 
For Western blotting transfected COS-1 cell lysates were used. The antibody was raised against a purified 
placental preparation of β-galactosidase and it binds the precursor and the mature form of the enzyme. 
 
RESULTS AND DISCUSSION 
In this study five patients from the Middle East with the infantile form of GM1-gangliosidosis, coming from 
four unrelated families, were studied at the molecular level. As far as we know, this is the first report of GLB1 
mutations in the Arabic population. All ten alleles were characterized and five different mutations were found, four 
of which are novel. For all the patients, the 16 exons and their flanking regions were amplified and directly 
sequenced on both strands. The data of the five patients analysed including their geographic origin and their 
genotypes, are summarized in Table 1.  
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Table 1. β-galactosidase Mutations in GM1-gangliosidosis Patients 
Patient Sex Ethnic 
origin 
GLB1 Base change Location 
exon/ 
intron 
Amino acid 
change 
Type of 
mutation 
Activity 
of β-gal 
enzyme  
% of 
normal 
mean 
Case 1 F Saudi 
Arabia 
[c.171C>G]* + [c.171C>G]*   Exon 2 p.Tyr57X  Nonsense 0.37 (SF) 
Exon 2 p.Arg49Cys Missense 0.73 (SF) Case 2 M Saudi 
Arabia 
[c.145C>T] + [c.245+1G>A]* 
Intron 2  Splicing  
Case 3 M United 
Arab 
Emirates  
[c.451G>T]* + [c.451G>T]* Exon 4 p.Asp151Tyr Missense 1.7 (L) 
Case 4.1 M United 
Arab 
Emirates 
[c.914+4G>A]* + [c.914+4G>A]* Intron 8  Splicing 1.27 (L) 
Case 4.2 F United 
Arab 
Emirates 
[c.914+4G>A]* + [c.914+4G>A]* Intron 8  Splicing 1.31 (SF) 
 
DNA variation numbering based on GenBank NM_000404.1, with +1 as A of the ATG start codon. Introns based on genomic 
GenBank NT_022517.16. Consensus nomenclature of mutations according to Dunnen and Antonarakis (2000). 
*Mutations that have not been previously reported.      SF: skin fibroblasts      L: leucocytes 
 
Patient 1, a girl from Saudi Arabia, was found to be homozygous for a c.171C>G transversion which creates a 
premature stop codon. This mutation has not been previously described. As expected, Northen blot analysis 
showed no total and no mRNA (Fig. 1).  
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Figure 1. Northern blot analysis of cultured fibroblasts from case 1, [c.171C>G] + [c.171C>G] and case 2 [c.145C>T] + 
[c.245+1G>A]. Top, probe was a 0.8 kb human β-gal cDNA. The lower panel represents the same blot hybridised with human 
β-actin cDNA to confirm RNA quality and relative loading. The size of the two transcripts was calculated on the basis of the 
0.24-9.5 kb RNA Ladder (Life technologies). Exposure time for both hybridisations was 24h. 
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The c.171C>G transversion was expressed in COS-1 cells. COS-1 cells transfected with the mutant vector 
showed absence of the 85kDa precursor protein (Fig. 2) and no catalytic activity (Table 2). The 64kDa mature 
protein is absent in all preparations including the positive control COS-1 cells transfected with normal β-gal 
vector. It was previously shown that in COS-1 cells transiently expressing human β-galactosidase, the 85kDa 
precursor is poorly processed into the mature 64kDa protein (Oshima et al., 1988; Morreau et al., 1989). The lack 
of processing is thought to be due to the transfection procedure and the fact that the amount of endogenous 
protective protein available in COS-1 cells is not sufficient to stabilize the bulk of over produced β-galactosidase 
molecules. 
 
 2 3 4 5 Mr 1 
 
 175 kDa 
 
83 kDa  
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Figure 2. Western blot analysis of non transfected and transfected Cos-1 cells. Lane 1 (negative control) corresponds to non 
transfected COS-1 cells. Lane 2 (positive control) are COS-1 cells transfected with normal β-gal vector. Lane 3 corresponds to 
COS-1 cells transfected with mutated vector Arg482His. Lane 4 and 5 are COS-1 cells transfected with mutated vectors Tyr57 
stop codon and Asp151Tyr respectively. Mr is the marker.  
 
 
The novel splice mutation in intron 2, c.245+1G>A was found in the heteroallelic state in Patient 2, a boy from 
Saudi Arabia. It is known that mutations in the gt/ag oligonucleotides at the 5’ and 3’ splice sites interfere with 
normal splicing (Padgett et al., 1986). The second mutation in this patient is a missense mutation, c.145C>T 
(p.Arg49Cys) previously found in the heteroallelic form in a Japanese patient with infantile GM1-gangliosidosis 
(Nishimoto et al., 1991). Fibroblasts from this patient showed substantially decreased amounts of total and mRNA 
in the Northern blot (Fig. 1). In order to delineate the separate effects of these two mutations expression studies or 
patients homozygous for either mutation are needed. 
Patient 3, a boy from the United Arab Emirates, was found to be homozygous for a G>T transition at nucleotide 
451, which results in an aspartic acid to tyrosine substitution in codon 151. This mutation, which has not been 
described before, was expressed in COS-1 cells. Transfected COS-1 cells showed complete lack of the 85kDa 
precursor protein (Fig. 2) and no enzymatic activity (Table 2). COS-1 cells transfected with another missense 
mutation (c.1445G>A, p.Arg482His) were run at the same time and they showed normal amounts of the 85kDa 
precursor protein (Fig. 2). It could be hypothesised that the aspartic acid residue at position 151, which is highly 
conserved, is important for the stability of the enzyme and its substitution leads to early degradation. For another 
missense mutation only three residues away from our mutation (p.Arg148Ser), Zhang et al. (2000) found abundant 
amounts of the precursor in COS-1 cells. More detailed studies on the structure and processing of the β-
galactosidase protein are needed in order to understand the impact of the various missense mutations on enzyme 
activity. 
 
Table 2. β-galactosidase Activity in COS-1 cells Transfected with Mutant β-galactosidase Constructs 
 β-galactosidase activity 
nmole/hr/mg protein 
% of wild-type 
COS-1 + wild type-pcDx 707 100 
COS-1 + Tyr57 stop codon-pcDx  87 0.56 
COS-1 + Asp151Tyr-pcDx  83 0 
COS-1 not transfected 83 − 
Each experiment was performed in triplicate and the values (nmol/hr/mg protein) are the mean values. 
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Patients 4.1 and 4.2 are siblings from the United Arab Emirates and they were found to be homozygous for a 
novel mutation, a transition of A>G in intron 8, c.914+4A>G which could affect the splicing process that normally 
removes the intron sequence from the primary RNA transcript. Unfortunately no skin fibroblasts were available to 
confirm this hypothesis by RNA studies. Consensus sequences for RNA splicing in higher eucaryotes is for the 5’ 
splice site (donor site) GUA (or G) AGU and for the 3’ splice site (acceptor site) C (or U) AG (Alberts et al., 
1994). The parents, who are first cousins, were found to be carriers for this mutation. Since no other mutation was 
detected by screening the GLB1 gene in these patients we assume that this mutation is responsible for the disease. 
The detection of five different mutations in four families studied indicates genetic heterogeneity of the β-
galactosidase deficiency in the Arabic population. Molecular characterization of more GM1-gangliosidosis 
patients in the Arabic as well as other populations will most likely yield more new mutations and allow a better 
understanding of genotype-phenotype correlations.  
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